Source: International Congress 2017 – Asthma management
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
P. Chanez (Marseille, France). A longitudinal follow-up of severe asthma patients receiving reslizumab. 3970

Member's Comments

No comment yet.

Related content which might interest you: Follow-up of patients with severe asthma receiving reslizumab: an FEV1 analysis Source: International Congress 2017 – Asthma management Year: 2017 The 1-year cost-effectiveness of roflumilast for the treatment of severe to very severe COPD patients Source: Eur Respir J 2007; 30: Suppl. 51, 194s Year: 2007 Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control Source: Annual Congress 2012 - Clinical diagnosis and treatment of adult asthma Year: 2012 “App” for uncontrolled moderate-severe asthma patients follow-up Source: International Congress 2017 – Biomarker-based asthma control Year: 2017 Follow-up of patients with severe eosinophilic asthma receiving mepolizumab for one year in specialized asthma clinics in Greece. Source: Virtual Congress 2020 – Clinical and laboratory pharmacology in asthma Year: 2020 The efficacy of salmeterol/fluticasone (SF) for 6-month therapy in severe COPD patients Source: Eur Respir J 2006; 28: Suppl. 50, 30s Year: 2006 Follow-up of patients with moderate-severe allergic asthma treated with omalizumab Source: Annual Congress 2010 - Asthma: clinical aspects and treatment Year: 2010 Cost analysis for patients with severe asthma receiving omalizumab treatment Source: International Congress 2019 – Clinical aspects of airway diseases Year: 2019 Effect of omalizumab on the risk of hospitalisation in patients with uncontrolled severe asthma in real-life. The PAX-LASER cohort Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010 Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV1 in patients with severe persistent allergic asthma irrespective of age Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005 Stop omalizumab: a multicenter follow up study after discontinuation in pediatric patients with severe asthma Source: Virtual Congress 2021 – Paediatric allergic asthma: novel therapeutics and monitoring approaches Year: 2021 Evolution of patients with severe asthma treated with mepolizumab Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Neomacrolides in the treatment of patients with severe asthma and/or bronchiectasis: A retrospective observational study Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010 The treatment with flunisolide in severe steroid asthmatics: the three-year follow-up study Source: Eur Respir J 2001; 18: Suppl. 33, 47s Year: 2001 Long-term efficacy of 1 year anti-inflammatory treatment in paediatric patients with mild persistent asthma Source: Eur Respir J 2004; 24: Suppl. 48, 379s Year: 2004 Mild improvement in symptoms and pulmonary function in a long-term follow-up of patients with TDI-induced asthma Source: Eur Respir J 2005; 26: Suppl. 49, 604s Year: 2005 Outcomes over the first two years of treatment with mepolizumab in severe asthma Source: Eur Respir J, 58 (6) 2101313; 10.1183/13993003.01313-2021 Year: 2021 A ten year follow-up of former paediatric asthma patients Source: Eur Respir J 2005; 26: Suppl. 49, 233s Year: 2005 Evaluating the efficacy of omalizumab in severe persistent asthma patients Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017 Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey Source: Eur Respir J 2013; 42: 1224-1233 Year: 2013